Boston Partners Has $625.50 Million Holdings in McKesson Co. (NYSE:MCK)

Boston Partners lifted its holdings in shares of McKesson Co. (NYSE:MCK - Free Report) by 24.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,096,301 shares of the company's stock after buying an additional 216,432 shares during the quarter. McKesson comprises approximately 0.8% of Boston Partners' investment portfolio, making the stock its 27th biggest holding. Boston Partners owned about 0.86% of McKesson worth $625,501,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. FMR LLC grew its holdings in McKesson by 17.3% during the third quarter. FMR LLC now owns 2,968,239 shares of the company's stock valued at $1,467,557,000 after purchasing an additional 438,423 shares during the period. The Manufacturers Life Insurance Company grew its holdings in McKesson by 55.8% during the third quarter. The Manufacturers Life Insurance Company now owns 1,189,377 shares of the company's stock valued at $588,048,000 after purchasing an additional 425,875 shares during the period. Janus Henderson Group PLC grew its holdings in McKesson by 126.8% during the third quarter. Janus Henderson Group PLC now owns 574,440 shares of the company's stock valued at $283,903,000 after purchasing an additional 321,119 shares during the period. Proficio Capital Partners LLC acquired a new position in McKesson during the fourth quarter valued at approximately $178,397,000. Finally, Raymond James Financial Inc. acquired a new position in McKesson during the fourth quarter valued at approximately $128,125,000. Institutional investors and hedge funds own 85.07% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other McKesson news, CEO Brian S. Tyler sold 8,961 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $600.66, for a total value of $5,382,514.26. Following the transaction, the chief executive officer now directly owns 69,625 shares in the company, valued at $41,820,952.50. The trade was a 11.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Leann B. Smith sold 188 shares of the company's stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $609.59, for a total transaction of $114,602.92. Following the completion of the transaction, the executive vice president now owns 1,051 shares in the company, valued at approximately $640,679.09. This represents a 15.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,689 shares of company stock valued at $11,187,351. 0.11% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on MCK shares. StockNews.com cut shares of McKesson from a "strong-buy" rating to a "buy" rating in a report on Friday, February 14th. Wells Fargo & Company lifted their price target on shares of McKesson from $641.00 to $691.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Morgan Stanley lifted their price target on shares of McKesson from $612.00 to $642.00 and gave the company an "overweight" rating in a research note on Tuesday, December 17th. Mizuho assumed coverage on shares of McKesson in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $630.00 price target on the stock. Finally, Bank of America cut their price target on shares of McKesson from $680.00 to $650.00 and set a "buy" rating on the stock in a research note on Monday, January 6th. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $649.36.

McKesson Stock Down 1.0 %

Shares of MCK stock traded down $6.91 during trading on Friday, reaching $659.45. The company's stock had a trading volume of 1,969,537 shares, compared to its average volume of 799,367. The business has a fifty day moving average price of $616.14 and a 200-day moving average price of $574.33. McKesson Co. has a one year low of $464.42 and a one year high of $670.79. The company has a market cap of $82.65 billion, a price-to-earnings ratio of 30.19, a price-to-earnings-growth ratio of 1.29 and a beta of 0.52.

McKesson (NYSE:MCK - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. Research analysts anticipate that McKesson Co. will post 32.77 EPS for the current year.

McKesson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Shareholders of record on Monday, March 3rd will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 0.43%. The ex-dividend date of this dividend is Monday, March 3rd. McKesson's dividend payout ratio (DPR) is currently 13.00%.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.